|
|
|
Course Title |
|
Pharmacology Update in Oncology: 2017 |
|
|
Faculty |
|
Rowena (Moe) Schwartz, PharmD, BCOP
Associate Professor
James L. Winkle College of Pharmacy
University of Cincinnati |
|
|
Program Overview |
|
Are you familiar with the new cancer drugs that the FDA has approved within the last year? Get introduced to these novel treatments while learning valuable tips to help you quickly identify drug classifications and use evidence-based interventions for management of these treatments.
|
|
|
|
Key Take-aways |
|
After participating in this enduring material, the participant should be able to:
1. Over the last year there has been both the approval of new drugs for cancer and the approval of new indications of many marketed agents for cancer care. As the use of an agent(s) evolves it is important that the healthcare team determine optimal strategies for care for clinical practice.
2. The dysregulation of apoptosis via overexpression of BCL-2 has been a target for drug therapy for many years. Venetoclax, a drug currently indicated for treatment of patients with chronic lymphocytic leukemia, has a potential for broader use.
3. The results from clinical trials provide the evidence and basis for the approval of new drugs and strategies in the management of cancer. The knowledge practitioners gain from practice should be shared broadly to optimize the benefits and minimize toxicities of these agents. |
|
|
Format |
|
Video/Audio with slides |
|
|
Credit Designation Statement(s) |
|
To earn CNE credit for this program, participants must view the entire program and complete the evaluation before the expiration date. The amount of CNE contact hours awarded for the session is indicated at the top of this page.
ONS is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC’s) Commission on Accreditation. Accreditation as an American Nurses Credentialing Center’s Commission provider refers only to its continuing nursing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products. ONS is accredited as a provider of continuing education by the California Board of Registered Nursing, Provider #2850. The contact hours earned from this educational opportunity may qualify for initial oncology nursing certification and renewal via ILNA. Visit www.oncc.org for complete details. |
|
|
Financial Disclosure Statement |
|
Speakers from the Oncology Nursing Society Annual Congress are expected to disclose to the readers any significant financial interest or other relationships with the manufacturer(s) of any commercial products. A vested interest may be considered to exist if a contributor is affiliated with or has a financial interest in commercial organizations that may have a direct or indirect interest in the subject matter. A “financial interest” may include, but is not limited to, being a shareholder in the organization; being an employee of the commercial organization; serving on an organization’s speaker’s bureau; or receiving research funding from the organization. An “affiliation” may be holding a position on an advisory board or some other role of benefit to the commercial organization.
|
|
|
Faculty Disclosure |
|
Rowena (Moe) Schwartz, PharmD, BCOP, has no financial interests or relationships to disclose. |
|
|
Planners and Managers Disclosure List |
|
Marilyn Hammer, PhD, DC, RN, has no financial interests or relationships to disclose.
Erica Corcoran, MSN, RN, OCN®, AOCNS®, is on the Genentech Speakers Bureau for Gazyvac.
Grace Dean, PhD, RN, has no financial interests or relationships to disclose.
Linda Eaton, PhD, RN, AOCN®, has no financial interests or relationships to disclose.
Margaret Grue, MSN, RN-BC, CRNI, OCN®, has no financial interests or relationships to disclose.
Jamilyn Kennell, MSN, RN, OCN®, has no financial interests or relationships to disclose.
Jeanette Pretorius, BSN, MBA, RN-BC, NE-BC, OCN®, has no financial interests or relationships to disclose.
Gary Shelton, DNP, NP; ANP-BC, AOCNP®, ACHPN, has no financial interests or relationships to disclose.
Lenise Taylor, RN, MN, AOCNS®, BMTCN™, has no financial interests or relationships to disclose.
Stephanie Jardine, BSN, RN, has no financial interests or relationships to disclose. |
|
|
Disclaimer |
|
This presentation is provided by the Oncology Nursing Society (ONS). ONS neither represents nor guarantees that the practices described herein will, if followed, ensure safe and effective patient care. The recommendations may not be appropriate for use in all circumstances. Those who use this information should make their own determinations regarding specific safe and appropriate patient care practices, taking into account the personnel, equipment, and practices available at the hospital or other facility at which they are located. ONS cannot be held responsible for any liability incurred as a consequence from the use or application of any of the contents of this presentation. Figures and tables are used as examples only. They are not meant to be all-inclusive, nor do they represent endorsement of any particular institution by ONS.
|
|
|
Product Disclosure |
|
Mention of specific products and opinions related to those products do not indicate or imply endorsement by ONS. |
|
|
Fee Statement |
|
Archived Session CNE Pricing Per Session
Members: Free
Nonmembers: $19.99 |
|
|
|
|